RxDoctor Payments DataLook up a doctor →

Joshua Perkel, MD

Urology · Macon, GANPI 1700897691

Payments from drug & device makers

$35,697in general payments, 2019–2025

Across 558 payments — averaging $63.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dendreon Pharmaceuticals LLC$8K
  • Astellas Pharma US Inc$7K
  • Bayer$5K
  • Boston Scientific$2K
  • Cook Medical LLC$2K
  • Medtronic$2K
  • plus $11K from 46 others

What the payments were for

  • Consulting fees$11,44432%
  • Speaking & faculty fees$3,0559%
  • Travel & lodging$4,42812%
  • Food & beverage$16,33246%
  • Education$4391%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,697 in reported general payments places this provider in the 90th percentile of 369 urology providers in Georgia.

See all urology providers in Georgia

Medicare billing

Part B allowed, 2024
$219,780
Medicare patients
675
Services billed
13,903

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide33$456,144
NubeqaDarolutamide22$295,777
GemtesaVibegron77$49,527
MyrbetriqMirabegron53$39,334
OrgovyxRelugolix11$29,445
Tamsulosin Hcl384$5,311
Finasteride398$4,838
Alfuzosin Hcl ErAlfuzosin Hcl166$3,730
Silodosin26$3,072
Potassium Citrate ErPotassium Citrate13$1,868
Solifenacin Succinate24$1,321
Dutasteride37$794
Doxycycline Monohydrate62$655
Oxybutynin Chloride57$647
Bicalutamide24$599

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$6,583$495,47786 claims
BayerNubeqa$4,990$295,77722 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$128$78,97288 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 369 urology providers in Georgia.

Other urology in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →